临床肿瘤学杂志

[1]Ahmedin J,Freddie B,Melissa MC,et al.Global Cancer Statis-tics[J].Ca Cancer J Clin,2011,61:69-90.

[2]Boyle P,Ferlay J.Cancer incidence and mortality in Europe,2004[J].Ann Oncol,2005,16(3):481-488.

[3]Rebecca S,Elizabeth W,Otis B,et al.The impact of eliminatingsocioeconomic and racial disparities on premature cancer deaths[J].CA Cancer J Clin,2011,61:212-236.

[4]Desmond RA,Soong SJ.Epidemiology of malignant melanoma[J].Surg Clin North Am,2003,83(1):1-29.

[5]郭军主译.黑色素瘤的预防、诊断和治疗[M].2版.北京:北京大学医学出版社,2008:51-55.

[6]Essner R,Lee JH,Wanek LA,et al.Contemporary surgicaltreatment of advanced-stage melanoma[J].Arch Surg,2004,139(9):961-966.

[7]Chun YS,Wang Y,Wang DY,et al.Prognostic value of S100Blevels and LDH levels in melanoma patients[J].J Clin Oncol,2008,26(Suppl):a9002.

[8]Lens M.Current clinical overview of cutaneous melanoma[J].Br J Nurs,2008,17(5):300-305.

[9]Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burdenof cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.

[10]Leiter U,Garbe C.Epidemiology of melanoma and nonmelanomaskin cancer--the role of sunlight[J].Adv Exp Med Biol,2008,624:89-103.

[11]High WA,Robinson WA.Genetic mutations involved in melano-ma:a summary of our current understanding[J].Adv Dermatol,2007,23:61-79.

[12]Curtin JA,Busam K,Pinkel D,et al.Somatic activation of KITin distinct subtypes of melanoma[J].J Clin Oncol,2006,24(26):4340-4346.

[13]Curtin JA,Fridlyand J,Kageshita T,et al.Distinct sets of ge-netic alterations in melanoma[J].N Engl J Med,2005,353(20):2135-2147.

[14]Ugurel S,Hildenbrand R,Zimpfer A,et al.Lack of clinical ef-ficacy of imatinib in metastatic melanoma[J].Br J Cancer,2005,92(8):1398-1405.

[15]Wyman K,Atkins MB,Prieto V,et al.Multicenter phaseⅡtri-al of high-dose imatinib mesylate in metastatic melanoma:Signifi-cant toxicity with no clinical efficacy[J].Cancer,2006,106(9):2005-2011.

[16]Mueller CS,Reichrath J.Histology of melanoma and nonmela-noma skin cancer[J].Adv Exp Med Biol,2008,624:215-226.

[17]Chang JW,Yeh KY,Wang CH,et al.Malignant melanoma inTaiwan:a prognostic study of 181 cases[J].Melanoma Res,2004,14(6):537-541.

[18]Hudson DA,Krige JE.Melanoma in black South Africans[J].JAm Coll Surg,1995,180(1):65-71.

[19]Lavie A,Desouches C,Casanova D,et al.Surgical managementof cutaneous malignant melanoma[J].Ann Chir Plast Esthet,2007,52(1):1-13.

[20]Sebastian G.Cutaneous malignant melanoma.Excision marginsand lymph node dissections[J].Hautarzt,2006,57(9):756-763.

[21]Lens MB,Dawes M,Goodacre T,et al.Excision margins in thetreatment of primary cutaneous melanoma:a systematic review ofrandomized controlled trials comparing narrow vs wide excision[J].Arch Surg,2002,137(10):1101-1105.

[22]Thomas JM,Newton-Bishop J,A’Hern R,et al.Excision mar-gins in high-risk malignant melanoma[J].N Engl J Med,2004,350(8):757-766.

[23]Veronesi U,Cascinelli N,Adamus J,et al.Narrow excision(1cm margin):a safe procedure for thin cutaneous melanoma.Theresults of an international randomized clinical trial[J].ArchSurg,1991,126(4):438-441.

[24]Joshua EL,Rory RD,Omar P,et al.Cutaneous melanoma:De-tecting it earlier,weigining management options[J].J FamPract,2007,56(1):18-28.

[25]Albertini JG,Elston DM,Libow LF,et al.Mohs micrographicsurgery for melanoma:a case series,a comparative study of im-munostains,an informative case report,and a unique mappingtechnique[J].Dermatol Surg,2002,28(8):656-665.

[26]Etzkorn JR,Cherpelis BS,Glass LF,et al.Mohs surgery formelanoma:rationale,advances and possibilities[J].Expert RevAnticancer Ther,2011,11(7):1041-1052.

[27]Mocellin S,Hoon DS,Pilati P,et al.Sentinel lymph node mo-lecular ultrastaging in patients with melanoma:a systematic re-view and meta-analysis of prognosis[J].J Clin Oncol,2007,25(12):1588-1595.

[28]Keijzer R,Bril H,van der Loo EM,et al.Important prognosticsignificance of a sentinel-node biopsy in patients with malignantmelanoma[J].Ned Tijdschr Geneeskd,2004,148(18):884-888.

[29]Donald LM,Thompson JF,Alistair JC,et al.Sentinel-node biop-sy or nodal observation in melanoma[J].N Engl J Med,2006,355(13):1307-1317.

[30]Lock-Andersen J,Horn J,Sjstrand H.Prognosis after sentinelnode biopsy in malignant melanoma[J].Ugeskr Laeger,2006,168(25):2457-2462.

[31]Mann GB,Coit DG.Does the extent of operation influence theprognosis in patients with melanoma metastatic to inguinal nodes?[J].Ann Surg Oncol,1999,6(3):263-271.

[32]Strobbe LJ,Jonk A,Hart AA,et al.Positive iliac and obturatornodes in melanoma:survival and prognostic factors[J].AnnSurg Oncol,1999,6(3):255-262.

[33]Karakousis CP.Therapeutic node dissections in malignant mela-noma[J].Semin Surg Oncol,1998,14(4):291-301.

[34]Wells KE,Stadelmann WK,Rapaport DP,et al.Parotid selec-tive lymphadenectomy in malignant melanoma[J].Ann PlastSurg,1999,43(1):1-6.

[35]Karakousis CP.The technique of popliteal lymph node dissection[J].Surg Gynecol Obstet,1980,151(3):420-423.

[36]Smith TJ,Sloan GM,Baker AR.Epitrochlear node involvementin melanoma of the upper extremity[J].Cancer,1983,51(4):756-760.

[37]Karakousis CP,Hena MA,Emrich LJ,et al.Axillary node dis-section in malignant melanoma:results and complications[J].Surgery,1990,108(1):10-17.

[38]Karakousis CP,Goumas W,Rao U,et al.Axillary node dissec-tion in malignant melanoma[J].Am J Surg,1991,162(3):202-207.

[39]Cascinelli N,Morabito A,Santinami M,et al.Immediate or de-layed dissection of regional nodes in patients with melanoma ofthe trunk:A randomised trial.WHO Melanoma Programme[J].Lancet,1998,351(9105):793-796.

[40]Carling T,Pan D,Ariyan S,et al.Diagnosis and treatment of in-terval sentinel lymph nodes in patients with cutaneous melanoma[J].Plast Reconstr Surg,2007,119(3):907-913.

[41]Thompson JF,Hunt JA,Shannon KF,et al.Frequency and du-ration of remission after isolated limb perfusion for melanoma[J].Arch Surg,1998,132(8):903-907.

[42]Lienard D,Eggermont AM,Kroon BB,et al.Isolated limb per-fusion in primary and recurrent melanoma:Indications and results[J].Semin Surg Oncol,1998,14(3):202-209.

[43]Lindner P,Doubrovsky A,Kam PCA,et al.Prognostic factorsafter isolated limb infusion with cytotoxic agents for melanoma[J].Ann Surg Oncol,2002,9(2):127-136.

[44]Buzzell RA,Zitelli JA.Favorable prognostic factors in recurrentand metastatic melanoma[J].J Am Acad Dermatol,1996,34(5):798-803.

[45]Wong SL,Coit DG.Role of surgery in patients with stageⅣmelanoma[J].Curr Opin Oncol,2004,16(2):155-160.

[46]Petersen RP,Hanish SI,Haney JC,et al.Improved survival withpulmonary metastasectomy:an analysis of 1720 patients with pul-monary metastatic melanoma[J].J Thorac Cardiovasc Surg,2007,133(1):104-110.

[47]Cascinelli N,Belli F,MacKie RM,et al.Effect of long-term ad-juvant therapy with interferon alpha-2a in patients with regionalnode metastases from cutaneous melanoma:a randomized trial[J].Lancet,2001,358(9285):866-869.

[48]Grob JJ,Dreno B,de la Salmoniere P,et al.Randomized trial ofinterferon alpha-2a as adjuvant therapy in resected primary mela-noma thicker than 1.5 mm without clinically detectable node me-tastases.French Cooperative Group on Melanoma[J].Lancet,1998,351(9120):1905-1910.

[49]Pehamberger H,Soyer H,Steiner A,et al.Adjuvant interferonalfa-2a treatment in resected primary stageⅡcutaneous melano-ma.Austrian Malignant Melanoma Cooperative Group[J].J ClinOncol,1998,16(4):1425-1429.

[50]Hancock BW,Wheatley K,Harris S,et al.Adjuvant interferonin high-risk melanoma:the AIM HIGH Study—United KingdomCoordinating Committee on Cancer Research randomized study ofadjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma[J].J Clin Oncol,2004,22(1):53-61.

[51]Eggermont AM,Suciu S,MacKie R,et al.Post-surgery adjuvanttherapy with intermediate doses of interferon alfa 2b versus obser-vation in patients with stageⅡb/Ⅲmelanoma(EORTC18952):randomized controlled trial[J].Lancet,2005,366(9492):1189-1196.

[52]Bajetta E.Adjuvant use of interferon alpha 2b is not justified inpatients with stageⅡb/Ⅲmelanoma[J].Nat Clin Pract Oncol,2008,5(1):4-5.

[53]Kirkwood JM,Manola J,Ibrahim J,et al.A pooled analysis ofeastern cooperative oncology group and intergroup trials of adju-vant high-dose interferon for melanoma[J].Clin Cancer Res,2004,10:1670-1677.

[54]Gogas H,Dafni U,Bafaloukos D,et al.A randomized phaseⅢtrial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma[J].J Clin On-col,2007,25(18Suppl):a8505.

[55]Eggermont AM,Suciu S,Santinami M,et al.Adjuvant therapywith pegylated interferon alfa-2b versus observation alone in re-sected stageⅢmelanoma:final results of EORTC 18991,a ran-domised phaseⅢtrial.EORTC Melanoma Group[J].Lancet,2008,372(9633):117-126.

[56]Verma S,Quirt I,McCready D,et al.Systematic review of sys-temic adjuvant therapy for patients at high risk for recurrent mela-noma[J].Cancer,2006,106(7):1431-1442.

[57]Geara FB,Ang KK.Radiation therapy for malignant melanoma[J].Surg Clin North Am,1996,76(6):1383-1398.

[58]Ang KK,Peters LJ,Weber RS,et al.Postoperative radiotherapyfor cutaneous melanoma of the head and neck region[J].Int JRadiat Oncol Biol Phys,1994,30(4):795-798.

[59]O'Brien CJ,Petersen-Schaefer K,Stevens GN,et al.Adjuvantradiotherapy following neck dissection and parotidectomy for me-tastatic malignant melanoma[J].Head&Neck,1997,19(7):589-594.

[60]Seung SK,Sneed PK,McDermott MW,et al.Gamma knife radi-osurgery for malignant melanoma brain metastases[J].Cancer JSci Am,1998,4(2):103-109.

[61]Radbill AE,Fiveash JF,Falkenberg ET,et al.Initial treatmentof melanoma brain metastases using gamma knife radiosurgery:anevaluation of efficacy and toxicity[J].Cancer,2004,101(4):825-833.

[62]Essner R.Surgical treatment of malignant melanoma[J].SurgClin North Am,2003,83(1):109-156.

[63]Falkson CI,Ibrahim J,Kirkwood JM,et al.PhaseⅢtrial of da-carbazine versus dacarbazine with tamoxifen versus dacarbazinewith interferon alfa-2b and tamoxifen in patients with metastaticmalignant melanoma:an Eastern Cooperative Oncology Groupstudy[J].J Clin Oncol,1998,16(5):1743-1751.

[64]Middleton M,Grob J,Aaronson N,et al.Randomized phaseⅢstudy of temozolomide versus dacarbazine in the treatment of pa-tients with advanced metastatic malignant melanoma[J].J ClinOncol,2000,18(1):158-166.

[65]Avril MF,Aamdal S,Grob JJ,et al.Fotemustine compared withdacarbazine in patients with disseminated malignant melanoma:aphaseⅢstudy[J].J Clin Oncol,2004,15(22):1118-1125.

[66]Bedikian AY,Millward M,Pehamberger H,et al.Bcl-2 anti-sense(oblimersen sodium)plus dacarbazine in patients with ad-vanced melanoma:the Oblimersen Melanoma Study Group[J].JClin Oncol,2006,24(29):4738-4745.

[67]Legha SS,Ring S,Eton O,et al.Development of a biochemo-therapy regimen with concurrent administration of cisplatin,vin-blastine,dacarbazine,interferon alfa,and interleukin-2 for pa-tients with metastatic melanoma[J].J Clin Oncol,1993,16(5):1752-1759.

[68]Chapman PB,Einhorn LH,Meyers ML,et al.PhaseⅢmulti-center randomized trial of the Dartmouth regimen versus dacarba-zine in patients with metastatic melanoma[J].J Clin Oncol,1999,17(9):2745-2751.

[69]Tentori L,Graziani G.Recent approaches to improve the antitu-mor efficacy of temozolomide[J].Curr Med Chem,2009,16(2):245-257.

[70]Boogerd W,de Gast GC,Dalesio O.Temozolomide in advancedmalignant melanoma with small brain metastases:can we with-hold cranial irradiation?[J].Cancer,2007,109(2):306-312.

[71]Schadendorf D,Hauschild A,Ugurel S,et al.Dose-intensifiedbi-weekly temozolomide in patients with asymptomatic brain me-tastases from malignant melanoma:a phaseⅡDeCOG/ADOstudy[J].Ann Oncol,2006,17(10):1592-1597.

[72]Krown SE,Niedzwiecki D,Hwu WJ,et al.PhaseⅡstudy oftemozolomide and thalidomide in patients with metastatic melano-ma in the brain:high rate of thromboembolic events(CALGB500102)[J].Cancer,2006,107(8):1883-1890.

[73]Rao RD,Holtan SG,Ingle JN,et al.Combination of paclitaxeland carboplatin as second-line therapy for patients with metastaticmelanoma[J].Cancer,2006,106(2):375-382.

[74]Ives NJ,Stowe RL,Lorigan P,et al.Chemotherapy comparedwith biochemotherapy for the treatment of metastatic melanoma:ameta-analysis of 18 trials involving 2,621 patients[J].J ClinOncol,2007,25(34):5426-5434.

[75]Geertsen PF,Gore ME,Negrier S,et al.Safety and efficacy ofsubcutaneous and continuous intravenous infusion rIL-2 in pa-tients with metastatic renal cell carcinoma[J].Br J Cancer,2004,90(6):1156-1162.

[76]Dillman RO,Selvan SR,Schiltz PM.Patient-specific dendritic-cell vaccines for metastatic melanoma[J].N Engl J Med,2006,355(11):1179-1181.

[77]Banchereau J,Ueno H,Dhodapkar M,et al.Immune and clini-cal outcomes in patients with stageⅣmelanoma vaccinated withpeptide-pulsed dendritic cells derived from CD34+progenitorsand activated with type I interferon[J].J Immunother,2005,28(5):505-516.

[78]崔传亮,迟志宏,袁香庆,等.肝动脉泵生物化疗治疗进展期黑色素瘤肝转移Ⅱ期临床研究[J].癌症,2008,27(8):845-850.

[79]Mao L,Si L,Chi Z,et al.A randomised phaseⅡtrial of 1month versus 1 year of adjuvant high-dose interferon a-2b in highrisk acral melanoma patients[J].Eur J Cancer,2011,47(10):1498-1503.

[80]Chi ZH,Li SM,Sheng XN,et al.Clinical presentation,histolo-gy,and prognoses of malignant melanoma in ethnic Chinese:Astudy of 522 consecutive cases[J].BMC Cancer,2011,11:85.

[81]Kong Y,Si L,Zhu YY,et al.Large-scale analysis of KIT aberra-tions in Chinese patients with melanoma[J].Clin Cancer Res,2011,17(7):1684-1691.

[82]Kong Y,Si L,Chi ZH,et al.Aberrations of KIT,BRAF,NRAS and PDGFRA in Chinese melanoma patients and their sig-nificance:large scale analysis of 644 patients[J].J Clin Oncol,2011,29(Suppl):a8564.

[83]Eggermont AM,Suciu S,Santinami M,et al.Adjuvant therapywith pegylated interferon alfa-2b versusobservation alone in resec-ted stageⅢmelanoma:final results of EORTC 18991,a ran-domized phaseⅢtrial[J].Lancet,2008,372(9633):117-126.

[84]Hodi FS,O'Day SJ,McDermott DF,et al.Improved survival withipilimumab in patients with metastatic melanoma[J].N Engl JMed,2010,363(8):711-723.

[85]Guo J,Si L,Kong Y,et al.A phaseⅡ,open label,single-armtrial of imatinib mesylate in patients with metastatic melanomaharboring c-Kit mutation or amplification[J].J Clin Oncol,2011,29(21):2904-2909.

[86]Curtin JA,Fridlyand J,Kageshita T,et al.Distinct sets of ge-netic alterations in melanoma[J].N Engl J Med,2005,353(20):2135-2147.

[87]Curtin JA,Busam K,Pinkel D,et al.Somatic activation of KITin 513 distinct subtypes of melanoma[J].J Clin Oncol,2006,24(26):4340-4346.

[88]Flaherty KT,Puzanov I,Kim KB,et al.Inhibition of mutated,activated BRAF in metastatic melanoma[J].N Engl J Med,2010,363(9):809-819.

[89]Makredes M,Hui SK,Kimball AB.et al.Melanoma in HongKong between 1983 and 2002:a decreasing trend in incidenceobserved in a complex socio-political and economic setting[J].Melanoma Res,2010,20(5):427-430.

[90]Xiang Y,Peng P,Wei L.Clinical analysis on 14 cases with ma-lignant melanoma in nasal cavity and sinus[J].Lin Chung Er BiYan Hou Tou Jing Wai Ke Za Zhi,2009,23(17):784-786.

[91]An JS,Wu LY,Li N,et al.Clinical analysis of 42 cases of pri-mary malignant melanoma in female genital tract[J].ZhonghuaFu Chan Ke Za Zhi,2007,42(5):320-324.

[92]Zhou HT,Zhou ZX,Zhang HZ,et al.Wide local excision couldbe considered as the initial treatment of primary anorectal malig-nant melanoma[J].Chin Med J(Engl),2010,123(5):585-588.

[93]Li ZY,Cai JQ,Cui XZ,et al.Outcome of malignant melanomain gastrointestinal tract:clinical analysis of 70 cases[J].Zhong-hua Wai Ke Za Zhi,2008,46(8):574-576.

[94]Luo LM,Huang HF,Pan LY,et al.Clinical analysis of 42 casesof primary malignant tumor in vagina[J].Zhonghua Fu Chan KeZa Zhi,2008,43(12):923-927.

[95]Yu H,Huang XY,Li Y,et al.Primary malignant melanoma ofthe esophagus:a study of clinical features,pathology,manage-ment and prognosis[J].Dis Esophagus,2011,24(2):109-113.

[96]Yang X,Ren GX,Zhang CP,et al.Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carbox-amide and cisplatin protocol are useful for oral mucosal melanoma[J].BMC Cancer,2010,10:623.

[97]Zhou Q,Zhang XS.Adjuvant interferon therapy for malignantmelanoma:the debate[J].Chin J Cancer,2010,29(11):907-913.